Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined 18F-FDG and 18F-FLT PET/CT imaging by C. Sachpekidis, H. Goldschmidt, K. Kopka, A. Kopp-Schneider, A. Dimitrakopoulou-Strauss

Get full text

Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb) by Ran Jin, Adesuwa S. Ogbomo, Neil A. Accortt, Lincy S. Lal, Geetanjali Bishi, Darcie Sandschafer, Jerome H. Goldschmidt

Get full text

The estrogen effect; clinical and histopathological evidence of dichotomous influences in dogs with spontaneous mammary carcinomas. by Karin U Sorenmo, Amy C Durham, Enrico Radaelli, Veronica Kristiansen, Laura Peña, Michael H Goldschmidt, Darko Stefanovski

Get full text

Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting by Shirish M. Gadgeel, Pragya Rai, Srinivas Annavarapu, Sartaj Alam, Jerome H. Goldschmidt, Howard (Jack) West, Melissa Santorelli, Renata Eiras Martins

Get full text

Clinical significance of cyclooxygenase-2 (COX-2) in multiple myeloma by M Tinguely, S Vallet, B Jenni, M Witzens-Harig, G Mechtersheimer, AD Ho, H Goldschmidt, D Jäger, M Boccadoro, M Ladetto

Get full text

Real‐world outcomes of 18,186 metastatic solid tumor outpatients: Baseline blood cell counts correlate with survival after immune checkpoint inhibitor therapy by Jerome H. Goldschmidt, Lin‐Na Chou, Philip K. Chan, Liwei Chen, Nicholas Robert, Joyce Kinsey, Katherine Pitts, Matt Nestor, Edwin P. Rock, Hillard M. Lazarus

Get full text

P926: DARATUMUMAB, BORTEZOMIB AND DEXAMETHASONE FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND SEVERE RENAL IMPAIRMENT: RESULTS FROM THE PHASE 2 GMMG-DA... by L. Leypoldt, M. Gavriatopoulou, B. Besemer, H. Salwender, M.-S. Raab, A. Nogai, C. Khandanpour, V. Runde, M. Zago, P. Martus, H. Goldschmidt, C. Bokemeyer, M. Dimopoulos, K. Weisel

Get full text

P972: INDIRECT COMPARISON OF TECLISTIMAB IN MAJESTEC-1 VERSUS PHYSICIAN’S CHOICE OF THERAPY IN LONG-TERM FOLLOW-UP OF TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA IN D... by K. Weisel, A. Chari, S. Z. Usmani, H. Goldschmidt, M.-V. Mateos, K. Qi, A. Londhe, S. Nair, X. Lin, L. Pei, E. Ammann, R. Kobos, J. Smit, T. Parekh, M. Slavcev, P. Moreau

Get full text

Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis. by Fernanda O Novais, Lucas P Carvalho, Joel W Graff, Daniel P Beiting, Gordon Ruthel, David S Roos, Michael R Betts, Michael H Goldschmidt, Mary E Wilson, Camila I de Oliveira, Phillip Scott

Get full text

P879: EXENT AND FLC MASS SPECTROMETRY FOR SEROLOGICAL IDENTIFICATION AND QUANTIFICATION OF MONOCLONAL IMMUNOGLOBULINS IN MULTIPLE MYELOMA by S. Huhn, A. M. Poos, E. K. Mai, M. Hänel, H. J. Salwender, J. Dürig, I. W. Blau, C. Scheid, K. C. Weisel, M. Munder, O. Berlanga, U. Bertsch, H. Goldschmidt, N. Weinhold

Get full text

P963: EVOLUTION OF TREATMENT PATTERNS AND OVERALL SURVIVAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING A SECOND LINE OF THERAPY BETWEEN 2012 AND 2020: ANALYSIS... by D. Kuter, H. Goldschmidt, D. Cella, M. T. Petrucci, P. Moreau, B. Durie, A. Juarez-Garcia, L. Trong, J. Gu, G. Hernandez Rivera, S. Dhanasiri, T. Marshall, J. Wang, L. Lacoin, K. Ramasamy, R. Vij

Get full text

P933: DARATUMUMAB (D) IN COMBINATION WITH VD OR D-RD IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS OF CASTOR AND POLLUX STUDIES IN PATIENTS WITH EARLY OR LATE RELAP... by A. Spencer, P. Moreau, M.-V. Mateos, H. Goldschmidt, K. Suzuki, M.-D. Levin, P. Sonneveld, S.-S. Yoon, S. Z. Usmani, K. Weisel, D. Reece, T. Ahmadi, H. Pei, W. Garvin Mayo, X. Gai, J. Carey, R. Carson, M. A. Dimopoulos

Get full text

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF T... by T. Facon, S. K. Kumar, T. Plesner, P. Moreau, N. Bahlis, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. P. Venner, K. Weisel, J. R. Mace, N. Raje, M. Tiab, M. Macro, L. Frenzel, X. Leleu, H. Pei, F. Borgsten, S. Z. Usmani

Get full text

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESS... by H Einsele, AD Cohen, M Delforge, J Hillengass, H Goldschmidt, K Weisel, M-S Raab, C Scheid, JM Schecter, KC De Braganca, H Varsos, T-M Yeh, L Wang, M Vogel, C Corsale, M Akram, L Pacaud, T Nesheiwat, M Agha, YC Cohen

Get full text

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES... by J. Hillengass, A. D. Cohen, M. Delforge, H. Einsele, H. Goldschmidt, K. Weisel, M.-S. Raab, C. Scheid, J. M. Schecter, K. C. De Braganca, H. Varsos, T.-M. Yeh, P. Mistry, T. Roccia, C. Corsale, M. Akram, L. Pacaud, T. Nesheiwat, M. Agha, Y. C. Cohen

Get full text

P05: DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE VERSUS LENALIDOMIDE AND DEXAMETHASONE ALONE IN PATIENTS WITH PREVIOUSLY TREATED MULTIPLE MYELOMA: OVERALL SURVIVAL RESULTS FROM... by MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, N Rabin, RZ Orlowski, K Suzuki, T Plesner, SS Yoon, D Ben Yehuda, PG Richardson, H Goldschmidt, D Reece, T Ahmadi, X Qin, W Garvin Mayo, X Gai, J Carey, R Carson, P Moreau

Get full text

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA... by K. Weisel, S. Kumar, P. Moreau, N. Bahlis, T. Facon, T. Plesner, R. Orlowski, S. Basu, H. Nahi, C. Hulin, H. Quach, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. Venner, N. Raje, M. Tiab1, M. Macro, L. Frenzel, X. Leleu, H. Pei, M Krevvata, R Carson, F. Borgsten, S. Usmani

Get full text

P958: REAL-LIFE CURRENT STANDARD OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSES FROM THE LOCOMMOTION STUDY by H. Einsele, P. Moreau, V. De Stefano, D. Dytfeld, E. Angelucci, R. Benjamin, H. Goldschmidt, N. W. van de Donk, B. Besemer, C. Scheid, R. Vij, E. I. ’. Groen-Damen, M. Semerjian, V. Strulev, J. M. Schecter, T. Roccia, T. Nesheiwat, R. Wapenaar, K. Weisel, M.-V. Mateos

Get full text

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY by P Rodriguez-Otero, B Dholaria, E Askari, D Reece, N van de Donk, A Chari, H Goldschmidt, A Krishnan, T Martin, M Mateos, D Morillo, C Rodriguez, L Rosinol, J San-Miguel, A Balari, R Wäsch, K Weisel, R Verona, S Lin, T Prior, M Wade, B Weiss, J Goldberg, A Oriol, P Hari

Get full text

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS by M Mateos, P Hari, N Bahlis, A Chari, NWCJ van de Donk, B Dholaria, AL Garfall, H Goldschmidt, KM Kortüm, A Krishnan, T Martin, D Morillo, A Oriol, D Reece, C Rodriguez, P Rodríguez-Otero, JF San-Miguel, SZ Usmani, R Verona, SXW Lin, TJ Prior, M Wade, B Weiss, JD Goldberg, E Askari

Get full text